FDA
-
-
-
-
-
-
-
Arbutus Biopharma (ABUS) Announces CEO, William Collier, to Retire December 31
-
-
-
-
-
-
-
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
-
-
-
-
-
-
-
Arbutus Biopharma (ABUS) Receives Authorization to Proceed with IND for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent
-
-
-
-
-
-
-
Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
-
-
-
-
-
-
-
Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results
-
251,639 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All